Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · IEX Real-Time Price · USD
1.080
+0.020 (1.89%)
May 17, 2024, 4:00 PM EDT - Market closed

Lineage Cell Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 1995
Revenue
8.9514.74.341.833.52
Upgrade
Revenue Growth (YoY)
-39.16%238.70%137.73%-48.05%-29.53%
Upgrade
Cost of Revenue
0.670.731.430.390.41
Upgrade
Gross Profit
8.2713.982.921.443.1
Upgrade
Selling, General & Admin
17.322.5118.2115.5724.03
Upgrade
Research & Development
15.7113.9933.9112.3217.95
Upgrade
Operating Expenses
33.0136.552.1327.8941.98
Upgrade
Operating Income
-24.73-22.52-49.21-26.45-38.88
Upgrade
Other Expense / Income
-1.443.21-6.19-4.56-19.76
Upgrade
Pretax Income
-23.29-25.73-43.02-21.89-19.12
Upgrade
Income Tax
-1.80.540-1.24-7.41
Upgrade
Net Income
-21.49-26.27-43.02-20.65-11.71
Upgrade
Shares Outstanding (Basic)
173170165150146
Upgrade
Shares Outstanding (Diluted)
173170165150146
Upgrade
Shares Change
1.69%3.22%9.64%3.10%14.68%
Upgrade
EPS (Basic)
-0.12-0.15-0.26-0.14-0.08
Upgrade
EPS (Diluted)
-0.12-0.15-0.26-0.14-0.08
Upgrade
Free Cash Flow
-29.240.65-23.9-19.79-32.31
Upgrade
Free Cash Flow Per Share
-0.170.00-0.14-0.13-0.22
Upgrade
Gross Margin
92.50%95.05%67.15%78.92%88.28%
Upgrade
Operating Margin
-276.50%-153.17%-1133.63%-1448.36%-1106.00%
Upgrade
Profit Margin
-240.20%-178.69%-990.99%-1130.83%-333.12%
Upgrade
Free Cash Flow Margin
-326.89%4.39%-550.59%-1084.01%-919.06%
Upgrade
EBITDA
-22.6-25.01-42.15-19.78-15.99
Upgrade
EBITDA Margin
-252.62%-170.07%-970.88%-1083.08%-454.82%
Upgrade
Depreciation & Amortization
0.690.730.872.113.13
Upgrade
EBIT
-23.29-25.73-43.02-21.89-19.12
Upgrade
EBIT Margin
-260.36%-175.01%-990.99%-1198.69%-543.84%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).